From the Journals
Oral TYK2 Inhibition in Atopic Dermatitis
-
By
February 5, 2026
-
4 min
-
1
ICP-332 reduced atopic dermatitis severity in adults.
-
2
75 participants aged 18-75 were involved.
-
3
The trial showed 64% of ICP-332 patients achieved a 75% improvement.
-
4
Treatment duration was 4 weeks.
-
5
No serious adverse events were reported.
-
6
Adverse events mainly mild to moderate.
-
7
The study underscores the need for phase 3 trials.
-
In a phase 2 randomized clinical trial, oral ICP-332 effectively reduced atopic dermatitis severity and pruritus in 75 adults over four weeks, demonstrating a favorable safety profile without serious adverse events. The trial showed significant mean reductions in the Eczema Area and Severity Index (EASI) score, with 64% of patients achieving a 75% improvement compared to only 8% with placebo. Conducted in China and led by Jinhua Xu, PhD, this study supports further investigation of ICP-332 as a potential treatment for moderate to severe atopic dermatitis.
-
1
ICP-332 reduced atopic dermatitis severity in adults.
-
2
75 participants aged 18-75 were involved.
-
3
The trial showed 64% of ICP-332 patients achieved a 75% improvement.
-
4
Treatment duration was 4 weeks.
-
5
No serious adverse events were reported.
-
6
Adverse events mainly mild to moderate.
-
7
The study underscores the need for phase 3 trials.
Listen Tab content
